Lyrica Patent Expiration Ushers In 9 Generic Competitors

Lyrica Patent Expiration Ushers In 9 Generic Competitors

Source: 
Xtalks
snippet: 

The moment that Pfizer has been dreading has finally arrived: the patent on its blockbuster nerve pain drug, Lyrica, has expired. The US Food and Drug Administration (FDA) authorized nine generic drug companies to make copycats of Lyrica (pregabalin), mere days after the expiration.